NYSE · Healthcare · Medical Devices · USA
Penumbra Inc is a large cap company (market value between $10 billion and $200 billion) in the Medical Devices industry.
Penumbra develops and markets medical devices for treating vascular conditions through minimally invasive procedures. Its product portfolio addresses thrombectomy, embolization, and access markets, removing blood clots and treating aneurysms and vessel disorders. The company distributes its products directly in the United States, Western Europe, Canada, Australia, and Singapore, plus via distributors internationally.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Penumbra Inc stock.
Overvalued: intrinsic value $74.23 per share, market price $322.41, margin of safety -334.3% (as of 2026-10-19).
Discounting its cash flows at 8.9% (average of 3 methods) values the shares at $74.23; the price of $322.41 is 334% above that value.
Leak Score: 53/100 on 11 of 12 signals (Weak Signal).
17 more funds hold it; the full list is part of the paid plan.
All 142 Medical Devices stocks
50 more in this industry show a wider margin of safety.
PEN is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 8.9% (average of 3 methods) values the shares at $74.23; the price of $322.41 is 334% above that value.
$74.23 per share (as of the 2026-10-19 close), against a market price of $322.41. That is a margin of safety of -334.3%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
53 out of 100, which we rate "Weak Signal", on 11 of 12 value investing signals.